 | • レポートコード：GIR-107A11933 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、NSCLC用標的薬HER2阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NSCLC用標的薬HER2阻害剤の種類別市場規模（アファチニブ、トラスツズマブ、その他）、用途別市場規模（NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・NSCLC用標的薬HER2阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Boehringer-Ingelheim、Roche、Mylan、Biocon ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アファチニブ、トラスツズマブ、その他 ・用途別分析2016年-2026年：NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん ・NSCLC用標的薬HER2阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・NSCLC用標的薬HER2阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・NSCLC用標的薬HER2阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・NSCLC用標的薬HER2阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・NSCLC用標的薬HER2阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Targeted Drug HER2 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Targeted Drug HER2 Inhibitors for NSCLC size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Targeted Drug HER2 Inhibitors for NSCLC market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Targeted Drug HER2 Inhibitors for NSCLC market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Afatinib
Trastuzumab
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Boehringer-Ingelheim
Roche
Mylan
Biocon
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Targeted Drug HER2 Inhibitors for NSCLC
1.2 Classification of Targeted Drug HER2 Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Type in 2020
1.2.3 Afatinib
1.2.4 Trastuzumab
1.2.5 Other
1.3 Global Targeted Drug HER2 Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Size by Region, (2016-2021)
1.5.3 North America Targeted Drug HER2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.4 Europe Targeted Drug HER2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.6 South America Targeted Drug HER2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug HER2 Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug HER2 Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug HER2 Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 Boehringer-Ingelheim
2.1.1 Boehringer-Ingelheim Details
2.1.2 Boehringer-Ingelheim Major Business
2.1.3 Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
2.1.4 Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Boehringer-Ingelheim Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
2.2.4 Roche Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Roche Recent Developments and Future Plans
2.3 Mylan
2.3.1 Mylan Details
2.3.2 Mylan Major Business
2.3.3 Mylan Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
2.3.4 Mylan Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Mylan Recent Developments and Future Plans
2.4 Biocon
2.4.1 Biocon Details
2.4.2 Biocon Major Business
2.4.3 Biocon Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
2.4.4 Biocon Targeted Drug HER2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Biocon Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug HER2 Inhibitors for NSCLC Players Market Share
3.2.3 Market Competition Trend
3.3 Targeted Drug HER2 Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021)
4.2 Global Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
5.2 Targeted Drug HER2 Inhibitors for NSCLC Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2026)
6.2 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2026)
6.3 North America Targeted Drug HER2 Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2026)
6.3.2 United States Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.3 Canada Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.4 Mexico Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2026)
7.2 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2026)
7.3 Europe Targeted Drug HER2 Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2026)
7.3.2 Germany Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.3 France Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.5 Russia Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.6 Italy Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2026)
8.2 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2026)
8.3 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Region (2016-2026)
8.3.2 China Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.3 Japan Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.4 South Korea Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.5 India Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.7 Australia Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2026)
9.2 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2026)
9.3 South America Targeted Drug HER2 Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2026)
9.3.2 Brazil Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9.3.3 Argentina Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2026)
10.2 Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2026)
10.3 Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2026)
10.3.2 Turkey Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.4 UAE Targeted Drug HER2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Targeted Drug HER2 Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021)
Table 5. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Region (2021-2026)
Table 6. Boehringer-Ingelheim Corporate Information, Head Office, and Major Competitors
Table 7. Boehringer-Ingelheim Major Business
Table 8. Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
Table 9. Boehringer-Ingelheim Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Roche Corporate Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
Table 13. Roche Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Mylan Corporate Information, Head Office, and Major Competitors
Table 15. Mylan Major Business
Table 16. Mylan Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
Table 17. Mylan Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Biocon Corporate Information, Head Office, and Major Competitors
Table 19. Biocon Major Business
Table 20. Biocon Targeted Drug HER2 Inhibitors for NSCLC Product and Solutions
Table 21. Biocon Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021)
Table 23. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Players (2019-2021)
Table 24. Breakdown of Targeted Drug HER2 Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 25. Targeted Drug HER2 Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 26. Targeted Drug HER2 Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 27. Targeted Drug HER2 Inhibitors for NSCLC New Entrants and Expansion Plans
Table 28. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021)
Table 29. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Type (2016-2021)
Table 30. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Forecast by Type (2021-2026)
Table 31. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021)
Table 32. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Forecast by Application (2021-2026)
Table 33. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 34. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 35. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 36. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 37. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 38. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 39. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 40. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 41. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 42. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 43. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 44. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 45. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 46. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 47. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 48. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 49. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million)
Table 50. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million)
Table 51. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 52. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 53. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 54. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 55. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 56. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 57. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 58. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 59. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 60. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 61. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 62. Middle East & Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Targeted Drug HER2 Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Type in 2020
Figure 3. Afatinib
Figure 4. Trastuzumab
Figure 5. Other
Figure 6. Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Application in 2020
Figure 7. Squamous Cell Carcinoma of NSCLC Picture
Figure 8. Adenocarcinoma of NSCLC Picture
Figure 9. Large Cell Carcinoma of NSCLC Picture
Figure 10. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 13. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Region in 2020
Figure 14. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Targeted Drug HER2 Inhibitors for NSCLC Market Drivers
Figure 20. Targeted Drug HER2 Inhibitors for NSCLC Market Restraints
Figure 21. Targeted Drug HER2 Inhibitors for NSCLC Market Trends
Figure 22. Boehringer-Ingelheim Recent Developments and Future Plans
Figure 23. Roche Recent Developments and Future Plans
Figure 24. Mylan Recent Developments and Future Plans
Figure 25. Biocon Recent Developments and Future Plans
Figure 26. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Players in 2020
Figure 27. Targeted Drug HER2 Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 28. Global Top 3 Players Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 29. Global Top 10 Players Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 30. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 31. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Type in 2020
Figure 32. Global Targeted Drug HER2 Inhibitors for NSCLC Market Share Forecast by Type (2021-2026)
Figure 33. Global Targeted Drug HER2 Inhibitors for NSCLC Revenue Share by Application in 2020
Figure 34. Global Targeted Drug HER2 Inhibitors for NSCLC Market Share Forecast by Application (2021-2026)
Figure 35. North America Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 36. North America Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 37. North America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 38. United States Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 39. Canada Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 40. Mexico Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Europe Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 42. Europe Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 43. Europe Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 44. Germany Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. France Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. United Kingdom Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Russia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Italy Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 50. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 51. Asia-Pacific Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 52. China Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Japan Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. South Korea Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. India Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Southeast Asia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Australia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South America Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 59. South America Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 60. South America Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 61. Brazil Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Argentina Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 64. Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 65. Middle East and Africa Targeted Drug HER2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 66. Turkey Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Saudi Arabia Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. UAE Targeted Drug HER2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Methodology
Figure 70. Research Process and Data Source
世界のNSCLC用標的薬ROS1阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug ROS1 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…- 世界のNSCLC用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…
- 世界の乳がん用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 世界の腫瘍壊死因子阻害薬市場 2021：企業別、地域別、種類・用途別 The Tumor Necrosis Factor Inhibitors Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization,…
- 未分化リンパ腫キナーゼ阻害剤の世界市場 2019年版：種類別（クリゾチニブ、セリチニブ、塩酸アレクチニブ）、用途別（NSCLC、乳がん、大腸がん、神経芽細胞腫、卵巣がん、その他） Scope of the Report: The worldwide market for Anaplastic Lymphoma Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the A…